Inovio Pharmaceuticals (NASDAQ:INO) Getting Somewhat Positive Media Coverage, Report Finds
News coverage about Inovio Pharmaceuticals (NASDAQ:INO) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.827535651335 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Inovio Pharmaceuticals, Inc. (INO) Short Interest Update (americanbankingnews.com)
- Inovio (INO) Q2 Loss Narrower Than Expected, Revenues Beat (finance.yahoo.com)
- Integrated Device Technology Inc (IDTI) and Inovio Pharmaceuticals Inc (INO) Seeing Increased Volatility in Session – Bulletin News (orobulletin.com)
- Placing the Spotlight on Inovio Pharmaceuticals Inc (INO): Technical Stock Update – Evergreen Caller (evergreencaller.com)
- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Posts Earnings Results (americanbankingnews.com)
Inovio Pharmaceuticals (NASDAQ:INO) traded up 1.28% on Friday, hitting $5.56. The stock had a trading volume of 1,077,056 shares. The stock’s market capitalization is $501.66 million. The company has a 50-day moving average price of $6.81 and a 200-day moving average price of $6.81. Inovio Pharmaceuticals has a 52 week low of $5.32 and a 52 week high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The business had revenue of $20.41 million during the quarter, compared to analyst estimates of $16.29 million. During the same period in the previous year, the company posted ($0.26) EPS. The firm’s revenue was up 229.2% compared to the same quarter last year. Equities research analysts anticipate that Inovio Pharmaceuticals will post ($0.93) earnings per share for the current fiscal year.
Several equities research analysts have issued reports on INO shares. Nomura restated a “buy” rating and issued a $40.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. HC Wainwright set a $13.00 price objective on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, July 7th. ValuEngine raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Tuesday, July 11th. Finally, Jefferies Group LLC reaffirmed a “neutral” rating and set a $38.00 price objective on shares of Inovio Pharmaceuticals in a research report on Monday, May 1st. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $20.78.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/inovio-pharmaceuticals-nasdaqino-getting-somewhat-positive-media-coverage-report-finds/1483558.html.
In related news, Director David B. Weiner sold 8,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the sale, the director now directly owns 740,956 shares of the company’s stock, valued at approximately $5,927,648. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.60% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.